The cell line used in this allograft model was derived from a prostate cancer that developed in Hi-MYC mice [19,26] that express the c-MYC oncogene in the prostate under the control of an androgen-regulated promoter (ARR2/probasin-Myc). Here, ARRB2 is linked to prostate carcinoma.